UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/541,749	03/03/2006	Lukas C. Amler	D0304 NP 9819		
23914 LOUIS J. WIL	7590 · 01/08/2008	EXAMINER .			
BRISTOL-MYERS SQUIBB COMPANY PATENT DEPARTMENT P O BOX 4000			GUSSOW, ANNE		
			ART UNIT	PAPER NUMBER	
PRINCETON,	NJ 08543-4000	1643			
			NOTIFICATION DATE	DELIVERY MODE	
			01/08/2008	ELECTRONIC	

## Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

uspatents@BMS.COM patents@bms.com eileen.immordino@bms.com

·	Application No.	Applicant(s)			
Office Assistant Communication	10/541,749	AMLER ET AL.			
Office Action Summary	Examiner	Art Unit			
	Anne M. Gussow	1643			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI	J. lely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status					
Responsive to communication(s) filed on  2a) ☐ This action is <b>FINAL</b> . 2b) ☑ This  3) ☐ Since this application is in condition for allowan closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro				
Disposition of Claims					
4)	ection requirement.  r.  epted or b) objected to by the Edrawing(s) be held in abeyance. See	e 37 CFR 1.85(a).			
11) The oath or declaration is objected to by the Ex		, ,			
Priority under 35 U.S.C. § 119					
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>					
Attachment(s)					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other: <u>Sequence all</u>	ate atent Application			

10/541,749 Art Unit: 1643

## **DETAILED ACTION**

## Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

To have a general inventive concept under PCT rule 13.1, the inventions need to be linked by a special technical feature. The special technical feature recited in claim 1 is a biomarker selected from the biomarkers in Table 4. In view of this Augustus (US PG PUB 2002/0102532, filed October 3, 2001) reads on the claim. Augustus teaches a method of treating cancer with agents targeting gene expression products. Augustus teaches one of these agents (SEQ ID No. 417) that is identical to 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 (SEQ ID No. 1 in table 4) of the instant invention. Therefore the technical feature recited in claim 1 is not special. Accordingly the groups are not so linked at to form a single general concept under rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Groups 1-139, claim(s) 1-4, drawn to a method for identifying a mammal that will respond therapeutically to a method of treating cancer by measuring the level of a biomarker selected from the listing in Tables 4 and 5. Each biomarker is a separate group.

2. The inventions listed as Groups 1-139 do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or

10/541,749

Art Unit: 1643

corresponding special technical features for the following reasons: As set forth above, in view of the teachings of Augustus, the groups are not so linked as to form a single general concept under PCT Rule 13.1 because the technical feature of claim 1 is not special.

3. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one

10/541,749

Art Unit: 1643

or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anne M. Gussow whose telephone number is (571) 272-6047. The examiner can normally be reached on Monday - Friday 8:30 am - 5 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Larry Helms can be reached on (571) 272-0832. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

LARRY R. HELMS, PH.D.
SUPERVICORY PATENT SXAMINER

Anne M. Gussow January 2, 2008

```
<!--StartFragment-->RESULT 1
US-09-969-708-417
; Sequence 417, Application US/09969708
; Patent No. US20020102532A1
; GENERAL INFORMATION:
  APPLICANT: Augustus, Meena
  TITLE OF INVENTION: Cancer Gene Determination and Therapeutic Screening Using Signa
  TITLE OF INVENTION: Sets
  FILE REFERENCE: 689290-70
  CURRENT APPLICATION NUMBER: US/09/969,708
  CURRENT FILING DATE: 2001-10-03
  PRIOR APPLICATION NUMBER: US/60/237,606
  PRIOR FILING DATE: 2000-10-03
  PRIOR APPLICATION NUMBER: US/60/237,608
  PRIOR FILING DATE: 2000-10-03
  PRIOR APPLICATION NUMBER: US/60/237,425
  PRIOR FILING DATE: 2000-10-03
  NUMBER OF SEQ ID NOS: 658
  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 417
  LENGTH: 2058
   TYPE: DNA
   ORGANISM: Homosapiens
US-09-969-708-417
 Query Match
                   100.0%;
                          Score 2058; DB 3; Length 2058;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 2058; Conservative
                        0; Mismatches
                                      0;
                                         Indels
                                                          0;
                                                 0:
                                                   Gaps
         1 CGGTTTCTGCTGGGTTTCTGAACTGCTGGGTTTCTGCTCCTCTGGAGATGCAGCGT 60
Qy
          Db
         1 CGGTTTCTGCTGGGTTTCTGAACTGCTGGGTTTCTGCTCCTCTGGAGATGCAGCGT 60
Qу
        Db
        121 ACACCTGCTCGCCTGCTCCCAGTAGCCCACCAAAGGTTTTCTACAGCCTCTGCTGTCCCC 180
Qy
          121 ACACCTGCTCGCCTGCTCCCAGTAGCCCACCAAAGGTTTTCTACAGCCTCTGCTGTCCCC 180
Db
       181 CTGGCCAAAACAGATACTTGGCCAAAGGACGTGGGCATCCTGGCCCTGGAGGTCTACTTC 240
Qу
          Db
       181 CTGGCCAAAACAGATACTTGGCCAAAGGACGTGGGCATCCTGGCCCTGGAGGTCTACTTC 240
       241 CCAGCCCAATATGTGGACCAAACTGACCTGGAGAAGTATAACAATGTGGAAGCAGGAAAG 300
Qy
          Db
       241 CCAGCCCAATATGTGGACCAAACTGACCTGGAGAAGTATAACAATGTGGAAGCAGGAAAG 300
       301 TATACAGTGGGCTTGGGCCAGACCCGTATGGGCTTCTGCTCAGTCCAAGAGGACATCAAC 360
Qу
          301 TATACAGTGGGCTTGGGCCAGACCCGTATGGGCTTCTGCTCAGTCCAAGAGGACATCAAC 360
Db
       361 TCCCTGTGCCTGACGGTGGTGCAACGGCTGATGGAGCGCATACAGCTCCCATGGGACTCT 420
Qу
          Db
       361 TCCCTGTGCCTGACGGTGGTGCAACGGCTGATGGAGCGCATACAGCTCCCATGGGACTCT 420
       421 GTGGGCAGGCTGGAAGTAGGCACTGAGACCATCATTGACAAGTCCAAAGCTGTCAAAACA 480
Qy
```

421 GTGGGCAGGCTGGAAGTAGGCACTGAGACCATCATTGACAAGTCCAAAGCTGTCAAAACA 480

Db

Qу	481	GTGCTCATGGAACTCTTCCAGGATTCAGGCAATACTGATATTGAGGGCATAGATACCACC	540
Db	481	GTGCTCATGGAACTCTTCCAGGATTCAGGCAATACTGATATTGAGGGCATAGATACCACC	540
Qy	541	AATGCCTGCTACGGTGGTACTGCCTCCTCTTCAATGCTGCCAACTGGATGGA	600
Db	541	AATGCCTGCTACGGTGGTACTGCCTCCTCTTCAATGCTGCCAACTGGATGGA	600
Qy	601	TCCTGGGATGGTCGTTATGCCATGGTGGTCTGTGGAGACATTGCCGTCTATCCCAGTGGT	660
Db	601	TCCTGGGATGGTCGTTATGCCATGGTGGTGGAGACATTGCCGTCTATCCCAGTGGT	660
Qy	661	AATGCTCGTCCCACAGGTGGGGCCGGAGCTGTGGCTATGCTGATTGGCCCAAAGGCCCCT	
Db	. 661	AATGCTCGTCCCACAGGTGGGGCCGGAGCTGTGGCTATGCTGATTGGCCCAAAGGCCCCT	
·Qy	721	CTGGCCCTGGAGCGAGGGCTGAGGGGAACCCATATGGAGAATGTGTATGACTTCTACAAA	780
Db	721	CTGGCCCTGGAGCGAGGGCTGAGGGGAACCCATATGGAGAATGTGTATGACTTCTACAAA	780
Qу	781	CCAAATTTGGCCTCGGAGTACCCAATAGTGGATGGGAAGCTTTCCATCCA	840
Db	781		840
Qy	841	CGGGCCTTGGATCGATGTTACACATCATACCGTAAAAAAATCCAGAATCAGTGGAAGCAA	900
Db	841		900
Qy	901	GCTGGCAGCGATCGACCCTTCACCCTTGACGATTTACAGTATATGATCTTTCATACACCC	960
Db	901		960
Qy	961	TTTTGCAAGATGGTCCAGAAGTCTCTGGCTCGCCTGATGTTCAATGACTTCCTGTCAGCC	1020
Db	961	TTTTGCAAGATGGTCCAGAAGTCTCTGGCTCGCCTGATGTTCAATGACTTCCTGTCAGCC	1020
Qу		AGCAGTGACACAAACCAGCTTATATAAGGGGCTGGAGGCTTTCGGGGGGCTAAAGCTG	1080
Db		AGCAGTGACACAAACCAGCTTATATAAGGGGCTGGAGGCTTTCGGGGGGGCTAAAGCTG	1080
Qy	1081	GAAGACACCTACACCAACAAGGACCTGGATAAAGCACTTCTAAAGGCCTCTCAGGACATG	1140
Db	1081	GAAGACACCTACACCAACAAGGACCTGGATAAAGCACTTCTAAAGGCCCTCTCAGGACATG	1140
Qy	1141	TTCGACAAGAAACCAAGGCTTCCCTTTACCTCTCCACTCACAATGGGAACATGTACACC	1200
Db	1141	TTCGACAAGAAAACCAAGGCTTCCCTTTACCTCTCCACTCACAATGGGAACATGTACACC	1200
Qу	1201	TCATCCCTGTACGGGTGCCTGGCCTCGCTTCTGTCCCACCACTCTGCCCAAGAACTGGCT	1260
Db	1201	TCATCCCTGTA CGGGTGCCTGGCCTCGCTTCTGTCCCACCACTCTGCCCAAGAACTGGCT	1260
Qy	1261	GGCTCCAGGATTGGTGCCTTCTCTTATGGCTCTGGTTTAGCAGCAAGTTTCTTTTCATTT	1320
Db	1261	GGCTCCAGGATTGGTGCCTTCTCTTATGGCTCTGGTTTAGCAGCAAGTTTCTTTTCATTT	1320
Qу	1321	CGAGTATCCCAGGATGCTGCTCCAGGCTCTCCCCTGGACAAGTTGGTGTCCAGCACATCA	1380
Db	1321	CGAGTATCCCAGGATGCTGCTCCAGGCTCTCCCCTGGACAAGTTGGTGTCCAGCACATCA	1380
Qу	1381	GACCTGCCAAAACGCCTAGCCTCCCGAAAGTGTGTCTCCTGAGGAGTTCACAGAAATA	1440

Db 138		).
Qy 144	1 ATGAACCAAAGAGAGCAATTCTACCATAAGGTGAATTTCTCCCCACCTGGTGACACAAAC 1500	)
Db 144		)
Qy 150	1 AGCCTTTTCCCAGGTACTTGGTACCTGGAGCGAGCAGCAGCAGCATCGCCGAAAGTAT 1560	)
Db 150	1 AGCCTTTTCCCAGGTACTTGGTACCTGGAGCGAGCGGCGGCAGCATCGCCGAAAGTAT 1560	)
Qy 156	1 GCCCGGCGTCCCGTCTAAAGGTGTTCTGCAGATCCATGGAAAGCTTCCTGGGAAACGTAT 1620	)
Db 156	1 GCCCGGCGTCCCGTCTAAAGGTGTTCTGCAGATCCATGGAAAGCTTCCTGGGAAACGTAT 1620	)
Qy 162	1 GCTAGCAGAGCTTCTCCCCGTGAATCATATTTTTAAGATCCCACTCTTAGCTGGTAAATG 1680	)
. Db 162	1 GCTAGCAGAGCTTCTCCCCGTGAATCATATTTTTAAGATCCCACTCTTAGCTGGTAAATG 1680	)
Qy 168	1 AATTTGAATCGACATAGTAGCCCCATAAGCATCAGCCCTGTAGAGTGAGGAGCCATCTCT 1740	)
Db 168	1 AATTTGAATCGACATAGTAGCCCCATAAGCATCAGCCCTGTAGAGTGAGGAGCCATCTCT 1740	)
Qy 174	1 AGCGGGCCCTTCATTCCTCCCATGCTGCAATCACTGTCCTGGGCTTATGGTGCCTATGG 1800	)
Db 174	1 AGCGGGCCCTTCATTCCTCCCATGCTGCAATCACTGTCCTGGGCTTATGGTGCCTATGG 1800	)
Qy 180	1 ACTAGGGGTCCTTTGTGAAAGAGCAAGATGGAGCAATGGAGAGAGA	)
Db 180	1 ACTAGGGGTCCTTTGTGAAAGAGCAAGATGGAGCAATGGAGAAGACCTCTTCCTGAAT 1860	)
Qy 186	1 CACTGGACTCCAGAAATGTGCATGCAGATCAGCTGTTGCCTTCAAGATCCAGATAAACTT 1920	)
Db 186	1 CACTGGACTCCAGAAATGTGCATGCAGATCAGCTGTTGCCTTCAAGATCCAGATAAACTT 1920	)
Qy 192	1 TCCTGTCATGTGTTAGAACTTTATTATTATTAATATTGTTAAACTTCTGTGCTGTTCCTG 1980	)
Db 192	1 TCCTGTCATGTGTTAGAACTTTATTATTATTAATATTGTTAAACTTCTGTGCTGTTCCTG 1980	)
Qy 198	1 TGAATCTCCAAATTTTGTACCTTGTTCTAAGCTAATATATAGCAATTAAAAAGAGAGAAA 2040	0
Db 198	1 TGAATCTCCAAATTTTGTACCTTGTTCTAAGCTAATATATAGCAATTAAAAAGAGAGAAA 2040	0
Qy 204	1 GAGAAAAAAAAAAA 2058 	
Db 204	1 GAGAAAAAAAAAAA 2058	